(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 December 2012 (27.12.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/176061 A9

(51) International Patent Classification:
C07D 417/12 (2006.01) *A61P 25/02* (2006.01)
C07D 417/14 (2006.01) *A61P 25/04* (2006.01)
A61P 29/00 (2006.01) *A61P 19/02* (2006.01)
A61P 1/04 (2006.01) *A61K 31/428* (2006.01)
A61P 13/00 (2006.01)

(21) International Application Number:
PCT/IB2012/001252

(22) International Filing Date:
21 June 2012 (21.06.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/499,989 22 June 2011 (22.06.2011) US

(71) Applicant *(for all designated States except US)*: **PURDUE PHARMA L.P.** [US/US]; One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901-3431 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **Shionogi & Co. Ltd.** [JP/JP]; 1-8, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP). **TAFESSE, Laykea** [US/US]; 11 Abbington Lane, Robbinsville, NJ 08691 (US). **ANDO, Shigeru** [JP/JP]; c/o Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825 (JP). **KUROSE, Noriyuki** [JP/JP]; c/o Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) Date of publication of this corrected version:
14 March 2013

(15) Information about Correction:
see Notice of 14 March 2013

(54) Title: TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF



(I)

(57) Abstract: The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof, where R_1, R_4, R_8, R_9, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI, an ulcer, IBD, and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof.

WO 2012/176061 A9